- Previous Close
1.1250 - Open
1.1240 - Bid 1.1000 x --
- Ask 1.1500 x --
- Day's Range
1.1000 - 1.1240 - 52 Week Range
0.6000 - 1.7590 - Volume
108,871 - Avg. Volume
4,098,369 - Market Cap (intraday)
2.286M - Beta (5Y Monthly) 1.70
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0000 - Earnings Date Mar 5, 2025 - Mar 10, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland. The company offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour predictive software. It also develops technology for use in the field of personalized medicine. The company was incorporated in 2001 and is based in Oxford, the United Kingdom.
www.physiomics.co.ukRecent News: PYC.L
View MorePerformance Overview: PYC.L
Trailing total returns as of 1/31/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PYC.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PYC.L
View MoreValuation Measures
Market Cap
2.29M
Enterprise Value
2.10M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.80
Price/Book (mrq)
8.09
Enterprise Value/Revenue
3.86
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-106.80%
Return on Assets (ttm)
-76.38%
Return on Equity (ttm)
-149.67%
Revenue (ttm)
570.56k
Net Income Avi to Common (ttm)
-609.35k
Diluted EPS (ttm)
-0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
191.07k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-373.53k